Improved reversals of cognitive decline in Alzheimer's Disease

Thursday, February 23, 2017 Mental Health News J E 4
The Bredesen Protocol™'s ReCODE™ supersedes MEND, in its advanced prevention and reversal of cognitive decline

SAN FRANCISCO, Feb. 23, 2017 /PRNewswire/ -- The inventor and developer of the original MEND protocol (metabolic enhancement for neurodegeneration), Dr. Dale Bredesen, has developed a more sophisticated and effective protocol, dubbed ReCODE™ for Reversal of Cognitive Decline. The MEND protocol was the first to result in the reversal of cognitive decline in patients with pre-Alzheimer's conditions and early Alzheimer's disease, as published in the journal Aging in 2014 by Dr. Bredesen. 

Since Dr. Bredesen's initial publication, he has made several new discoveries, including the recognition and naming of specific subtypes of Alzheimer's disease (published by Bredesen in 2015) and the recognition of specific toxic exposures contributing to Alzheimer's disease (published in 2015 and 2016).  These discoveries and others led to the development of ReCODE™, the new version of The Bredesen Protocol™. "These latest discoveries greatly enhance our ability to determine the underlying causes of cognitive decline, thus improving our overall approach to reversing the decline, and strengthening the ability of our MPI Cognition Certified™ physicians to help their patients in need," said Bredesen.

The ReCODE™ version of The Bredesen Protocol™ will be the centerpiece of the upcoming Alzheimer's Reversal Immersion Program, the kickoff for an intensive one-year application of the improved protocol, which is limited to 100 qualifying pre-Alzheimer's, early stage, and mid-stage Alzheimer's participants, held in Indian Wells, California, on March 24 through 27, 2017. 

Bredesen was the Founding President and CEO of the Buck Institute for Age Research in Novato, California, and Director of the Easton Center for Alzheimer's Research at UCLA.


800 450


To view the original version on PR Newswire, visit:




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
An Open Letter from Bruce Linton Updating on Mettr...
Technical Reports on Biotech Stocks -- Juno Therap...